Wombat Capital Markets Advised Regis Technologies On Its Sale To Esteve
New York, NY – Wombat Capital Markets advised Regis Technologies (“REGIS”), a United States-based Contract Development and Manufacturing Organization (CDMO) headquartered in Morton Grove, IL, on its sale to Esteve Healthcare, holding to Esteve Group including ESTEVE CDMO. ESTEVE CDMO is a global pure-play third-party CDMO, specializing in high-quality small-molecule active pharmaceutical ingredients and pharmaceutical intermediates, providing technologies such as Spray Drying and high-potency APIs (HPAPIs) manufacturing. The transaction closed on July 30, 2025.
This strategic move allows ESTEVE CDMO a physical presence in the United States, expanding its contract development and manufacturing solutions for innovative small-molecule active pharmaceutical ingredients (APIs) across the entire drug development lifecycle from pre-clinical to commercial manufacturing.
For over 65 years, Regis Technologies has been a U.S.-based API CDMO, offering a broad spectrum of services, including process research & development, analytical & stability, cGMP API manufacturing, CMC support, and a variety of chromatography products.
“We are proud to strengthen our CDMO solutions for pharmaceutical innovators through this acquisition, while welcoming around 70 skilled professionals to our U.S. team”, said Joan Petit, Chief Industrial Operations Officer of ESTEVE.
Andrea Oro, Global Head of Commercial Operations and Strategy and US Managing Director, added, “This acquisition enhances our early-stage development capabilities, and expands our global manufacturing footprint, allowing us to have an integrated service offering to better respond to our customers’ needs.”
“We are happy to join a company that shares our same values, a company that is also family-owned, with more than 90 years of experience, that is committed to people and focused on delivering long-term value to customers,” added Scott Aladeen, President and CEO of Regis Technologies.
Jean-Jacques (John) Mondoloni, Managing Partner at Wombat Capital Markets, remarked, “We very much enjoyed the close relationship that we have developed with the Regis team through this process. We have been following Regis for so many years; it was a true honor to have been selected for this mandate. This additional transaction in the API CDMO sector reinforces our position as the go-to advisor for CDMO M&A advisory, bringing years of sector-focused industry knowledge and track records to assist our clients in getting deals done with a favorable outcome for management and shareholders.”
Scott Aladeen commented further, “Thank you for the tremendous support you provided without which we absolutely could not have done this deal. Your focus and engagement on this deal at the exclusion of others was greatly appreciated – you were continuously available and working on our behalf, and your negotiating skill, as well as your tremendous technical skill in the mechanics of these deals was invaluable. From the initial preparation of the CIM through the preparation of the final closing statement I was in constant awe of the quality and volume of work you did on our behalf.”
About Regis Technologies (www.registech.com)
Regis Technologies, Inc., partners with pharmaceutical and biotechnology companies to help advance drug candidates to market. Our services streamline and support discovery, lead molecule development and drug commercialization – from process development and analytical development, to stability services and cGMP API manufacturing. Our facilities are routinely inspected by the FDA and other global regulatory authorities. With our extensive organic chemistry & separations expertise, Regis also manufactures an innovative line of proprietary chromatography products sold throughout the world. Regis was founded in 1956 by Dr. Louis Glunz III in Chicago.
About Esteve (www.esteve.com)
ESTEVE is a global pharmaceutical company with a clear purpose: to improve people’s lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA. ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition to our innovative pharma business, we offer comprehensive Contract Development and Manufacturing services (CDMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, China, and the USA. ESTEVE’s strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.
About Wombat Capital Markets (www.wombatcapital.com)
Founded in 2009, Wombat Capital is a cross-border investment bank providing Mergers and Acquisitions advisory services to entrepreneurs, board of directors, financial investors, private and public companies. With offices in New York, Los Angeles and Paris, Wombat Capital focuses on the lower middle market of the Pharmaceutical Outsourcing, Medical Devices and Diagnostics sectors.
*Testimonials related to Wombat Capital’s services: Please note that these testimonials may not be representative of the experience of other customers, and these testimonials are no guarantee of future performance or success.